Transcript Presentation by Dr Harden

Mesothelioma: your questions and future
treatment options
Susie Harden 1/4/11
Future possibilities in Cambridge




First line studies
Second line studies
Phase 1 studies
Biobank: potential for individually tailored
treatments in the future?
First line studies coming soon

MESO 2: phase II study of adding
vorinostat to pemetrexed /cisplatin
[this agent is a histone deacetylase inhibitor and acts to
‘unblock’ certain genes in tumour cells

ADAM: Phase II study of pegylated
arginine deaminase/placebo
[when chemotherapy not indicated in ASS (arginosuccinate
synthetase) negative patients. (this agent depletes tumours
of an essential amino acid – arginine)]
Secondline studies
No standard treatment but re-challenge with
pemetrexed if good first time response
accepted
No imminent trials in Cambridge
Phase 1 studies in Cambridge

S222611 SHINOGI
[a dual EGFR and HER2 small molecule inhibitor]

Radiotherapy (your feedback please!)
Tomotherapy dose-wash diagram
Over to you!
Any questions?
Any suggestions?